ALAN-MICHAEL VARGAS: Open Payments
NPI 1619283991 · PARACHUTE, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,043 in 50 payments from 18 companies in 2025. Trend: 2023 $1,074 · 2024 $1,051 · 2025 $1,043
Food & beverage: $1,043
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $200 |
| AstraZeneca Pharmaceuticals LP | 11 | $188 |
| Astellas Pharma US Inc | 5 | $120 |
| GlaxoSmithKline, LLC. | 5 | $98 |
| Lundbeck LLC | 3 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
| Amgen Inc. | 3 | $45 |
| Neurocrine BioSciences, Inc. | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
Products named: UBRELVY, Veozah, REXULTI, BREZTRI, QULIPTA, FARXIGA, TRELEGY ELLIPTA, CAPLYTA.
Industry payments across CO — which companies pay providers there.
